摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-甲氧基吡啶-2-基)乙酸乙酯 | 91012-88-3

中文名称
2-(3-甲氧基吡啶-2-基)乙酸乙酯
中文别名
——
英文名称
ethyl 2-(3-methoxypyridin-2-yl)acetate
英文别名
——
2-(3-甲氧基吡啶-2-基)乙酸乙酯化学式
CAS
91012-88-3
化学式
C10H13NO3
mdl
——
分子量
195.218
InChiKey
XILNZILJKRZCDR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    268.8±25.0 °C(Predicted)
  • 密度:
    1.109±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    48.4
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933399090

SDS

SDS:e2c9bd97b6937640dd0d7c86cee0bec1
查看

反应信息

  • 作为反应物:
    描述:
    2-(3-甲氧基吡啶-2-基)乙酸乙酯1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物potassium acetatecaesium carbonateN,N-二异丙基乙胺Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下, 以 四氢呋喃1,4-二氧六环二甲基亚砜N,N-二甲基甲酰胺甲苯 为溶剂, 反应 11.03h, 生成 3-chloro-7-(2-hydroxypropan-2-yl)-4-(3-(5-methoxy-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin-2(3H)-yl)-2-methylphenyl)-9H-carbazole-1-carboxamide
    参考文献:
    名称:
    SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS
    摘要:
    公开的是Formula (I)的化合物,其中:两条虚线代表两个单键或两个双键;Q是:R1是F、Cl、—CN或—CH3;R2是Cl或—CH3;R3是—C(CH3)2OH或—CH2CH2OH;Ra是H或—CH3;每个Rb独立地是F、Cl、—CH3和/或—OCH3;n为零、1或2。还公开了将这些化合物用作Bruton酪氨酸激酶(Btk)抑制剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面非常有用,如自身免疫疾病和血管疾病。
    公开号:
    US20140378475A1
  • 作为产物:
    描述:
    3-甲氧基-2-甲基吡啶碳酸二乙酯正丁基锂二异丙胺 作用下, 以 四氢呋喃正己烷 为溶剂, 以81%的产率得到2-(3-甲氧基吡啶-2-基)乙酸乙酯
    参考文献:
    名称:
    SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS
    摘要:
    公开的是Formula (I)的化合物,其中:两条虚线代表两个单键或两个双键;Q是:R1是F、Cl、—CN或—CH3;R2是Cl或—CH3;R3是—C(CH3)2OH或—CH2CH2OH;Ra是H或—CH3;每个Rb独立地是F、Cl、—CH3和/或—OCH3;n为零、1或2。还公开了将这些化合物用作Bruton酪氨酸激酶(Btk)抑制剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面非常有用,如自身免疫疾病和血管疾病。
    公开号:
    US20140378475A1
点击查看最新优质反应信息

文献信息

  • Divergent and Regioselective Synthesis of Pyrazolo[1,5-<i>a</i>]pyridines and Imidazo[1,5-<i>a</i>]pyridines
    作者:Katrina M. Mennie、Michael H. Reutershan、Catherine White、Bruce Adams、Bridget Becker、James Deng、Jason D. Katz、Elisabeth LaBlue、Kaila Margrey、Josep Saurí
    DOI:10.1021/acs.orglett.1c01431
    日期:2021.6.18
    ubiquitous in pharmaceuticals and drug-like compounds; however, regioselective synthesis has proved challenging. Herein we report our efforts to develop a regioselective method for the synthesis of pyrazolo[1,5-a]pyridines and the serendipitous discovery of a protocol for the regioselective formation of imidazo[1,5-a]pyridines. Together, these transformations allow for the rapid and selective formation
    氮杂环在药物和类药物化合物中无处不在;然而,区域选择性合成已被证明具有挑战性。在此,我们报告了我们为开发合成吡唑并[1,5- a ]吡啶的区域选择性方法所做的努力,并偶然发现了一种用于区域选择性形成咪唑并[1,5- a ]吡啶的方案。总之,这些转化允许从一个共同的中间体快速和选择性地形成两个重要的杂环基序。
  • 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774
    申请人:ANDERSSON Johan
    公开号:US20100331341A1
    公开(公告)日:2010-12-30
    The present invention relates to compounds of formula (I), wherein R 1 is heteroaryl or heterocyclyl, optionally substituted; R 2 is C 1-4 alkyl, heterocyclyl, C 1-4 alkylaryl, C 1-4 alkylheteroaryl, carbocyclyl, C 1-4 alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R 3 is hydrogen or C 1-4 alkyl, or R 2 and R 3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R 4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.
    本发明涉及公式(I)的化合物,其中R1是杂环芳基或杂环烷基,可选择性取代;R2是C1-4烷基,杂环烷基,C1-4烷基芳基,C1-4烷基杂环芳基,环烷基,C1-4烷基杂环烷基,杂环烷基-杂环芳基,芳基-杂环烷基,环烷基-杂环芳基,杂环烷基-芳基,可选择性取代;R3是或C1-4烷基,或R2和R3可以与原子一起形成含有4、5或6个环形成原子的饱和环系统,并可选择性取代;R4是,卤素,甲基或甲基;含有所述化合物的药物组合物以及所述化合物在治疗中的使用,例如用于治疗认知障碍。本发明还涉及制备中间体的新方法。
  • [EN] CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE CARBAZOLE-CARBOXAMIDE UTILES COMME INHIBITEURS DE KINASES
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2014210087A1
    公开(公告)日:2014-12-31
    Disclosed are compounds of Formula (I); and salts thereof, wherein:Formula (II); Q is: R1 is -C(CH3)2OH, -NHC(=0)C(CH3)3, -N(CH3)2, or -CH2Rd; R2 is CI or -CH3; R3 is H, F, or -CH3; Ra is H or -CH3; Rb is H, F, CI, or -OCH3 Rc is H or F; and Rd is -OH, -OCH3, -NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    公开了Formula (I)的化合物及其盐,其中:Formula (II);Q是:R1为-C(CH3)2OH,-NHC(=0)C( )3,-N( )2,或-CH2Rd;R2为CI或- ;R3为H,F或- ;Ra为H或- ;Rb为H,F,CI或-O ;Rc为H或F;Rd为-OH,-O ,-NHC(=0) ,或Formula (III)。还公开了使用这些化合物作为Bruton酪氨酸激酶(Btk)抑制剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域的疾病或障碍方面具有用途,如自身免疫疾病和血管疾病。
  • 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives
    申请人:ASTRAZENECA AB
    公开号:US20130296296A1
    公开(公告)日:2013-11-07
    The present invention relates to compounds of formula (I), wherein R 1 is heteroaryl or heterocyclyl, optionally substituted; R 2 is C 1-4 alkyl, heterocyclyl, C 1-4 alkylaryl, C 1-4 alkylheteroaryl, carbocyclyl, C 1-4 alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R 3 is hydrogen or C 1-4 alkyl, or R 2 and R 3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R 4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.
    本发明涉及式(I)的化合物,其中R1是杂环芳基或杂环基,可选地被取代;R2是C1-4烷基,杂环基,C1-4烷基芳基,C1-4烷基杂环芳基,环基,C1-4烷基杂环基,杂环基-杂环芳基,芳基-杂环基,环基-杂环芳基,杂环基-芳基,可选地被取代;R3是或C1-4烷基,或R2和R3可以与原子一起形成4、5或6个环形成原子的饱和环系统,可选地被取代;R4是、卤素、甲基或甲基;以及含有所述化合物的制药组合物和所述化合物在治疗中的用途,例如用于治疗认知障碍。本发明还涉及在其制备中有用的新中间体
  • SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLES CARBOXAMIDE COMPOUNDS
    申请人:Bristol-Myers Squibb Company
    公开号:US20160194338A1
    公开(公告)日:2016-07-07
    Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R 1 is F, Cl, —CN, or —CH 3 ; R 2 is C 1 or —CH 3 ; R 3 is —C(CH 3 ) 2 OH or —CH 2 CH 2 OH; R a is H or —CH 3 ; each R b is independently F, Cl, —CH 3 , and/or —OCH 3 ; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    本发明涉及式(I)的化合物,其中:两个点状线代表两个单键或两个双键;Q为:R1为F、Cl、—CN或—CH3;R2为C1或— ;R3为—C( )2OH或—CH2CH2OH;Ra为H或— ;每个Rb独立地为F、Cl、— 和/或—O ;n为零、1或2。本发明还涉及使用这些化合物作为布鲁顿酪氨酸激酶(Btk)抑制剂的方法,以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病进展方面是有用的,例如自身免疫性疾病和血管疾病。
查看更多